Novavax 疫苗来了

Ottawa005

知名会员
注册
2009-09-03
消息
671
荣誉分数
292
声望点数
173

Novavax files for COVID-19 vaccine approval in Canada​

Novavax announced Monday in a news release that it had completed a rolling submission to Health Canada for authorization of its two-dose COVID-19 vaccine, a long-awaited development for the Maryland company, which has struggled to bring its doses for use in the global inoculation campaign.
Shares of Novavax rose about 11 per cent before the opening bell after the company also said it had filed an application for emergency use for the vaccine to Canada as well as the European Medicines Agency.

The Novavax shot was shown to be more than 90 per cent effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial, with no reports of rare blood clot or heart inflammation issues.
 
如果我打第三针的话,绝对不换新的疫苗。
 
最后编辑:
不是有那么一句话:
吃屎都赶不上热的。
 
比起现在市面上的疫苗,这个疫苗应该安全性好点吧 @贵圈
质量控制有问题,生产的疫苗达不到三期实验时使用的疫苗,迟迟不能获批上市,所以虽然理论上更安全,实际上可能更危险。
 
美国诺瓦瓦克斯Novavax公司和印度血清研究所宣布,印度尼西亚国家药品和食品管理局已授予诺瓦瓦克斯两针型重组蛋白新冠疫苗紧急使用授权(EUA)。该疫苗将由印度血清研究所生产,并以COVOVAX品牌在印度尼西亚销售。诺瓦瓦克斯预计将立即开始向印尼运送首批疫苗。

印度生产的,敢用吗?
 
美国诺瓦瓦克斯Novavax公司和印度血清研究所宣布,印度尼西亚国家药品和食品管理局已授予诺瓦瓦克斯两针型重组蛋白新冠疫苗紧急使用授权(EUA)。该疫苗将由印度血清研究所生产,并以COVOVAX品牌在印度尼西亚销售。诺瓦瓦克斯预计将立即开始向印尼运送首批疫苗。

印度生产的,敢用吗?
北美大部分药都是印度生产的
 
质量控制有问题,生产的疫苗达不到三期实验时使用的疫苗,迟迟不能获批上市,所以虽然理论上更安全,实际上可能更危险。
有道理。个人对Novavax期待已久,但是它迟迟不能上市。虽然也怀疑过,是否因为被大药厂打压,但是它本身生产能力不足也是硬伤。即使它的有效性得到验证,蛋白重组技术的安全性也更令人放心,但是生产方面的安全性如何保证?可没有这方面的数据吧。因此,对Novavax所谓的安全有效,也应该保持警惕。
 

总部位于美国并在加拿大设有生产厂的 Novavax 已正式向加拿大卫生部提交其疫苗使用申请,如果获批,加拿大将有一种新型 COVID-19 疫苗上市,而生产工厂就在加拿大的蒙特利尔市。
加拿大第一个生产新冠疫苗的工厂今年6月在蒙特利尔举行开业典礼,按照加拿大国家研究委员会NRC(National Research Council of Canada)发布的新闻稿,这家新工厂称为“Biologics Manufacturing Centre”,位于蒙特利尔的Royalmount地区,该项目的建设阶段已提前完工,要等待完成相关审批手续之后,估计从2022年正式开始投入生产。
 
如果有得打,我会选择加拿大品牌作为第三针。支持加拿大科技产业,加拿大人的责任!
 
我是不想打第三针了,不是病毒毒性减弱了吗?為个感冒去冒險不值得
 
这款疫苗是加拿大第一个本土生产的,终于有了自己制造的疫苗。

今天印度尼西亚成为世界第一个紧急批准这款疫苗的国家。
 

Novavax files for COVID-19 vaccine approval in Canada​

Novavax announced Monday in a news release that it had completed a rolling submission to Health Canada for authorization of its two-dose COVID-19 vaccine, a long-awaited development for the Maryland company, which has struggled to bring its doses for use in the global inoculation campaign.
Shares of Novavax rose about 11 per cent before the opening bell after the company also said it had filed an application for emergency use for the vaccine to Canada as well as the European Medicines Agency.

The Novavax shot was shown to be more than 90 per cent effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial, with no reports of rare blood clot or heart inflammation issues.
如果有得打,我会选择加拿大品牌作为第三针。支持加拿大科技产业,加拿大人的责任!
那谁说得对,原理上安全很多,但是,也看质量。

一针RNA,我喊了一声美,
二针还是RNA,没有喝酒人自醉,
三针改打组蛋白,保证你的小脸儿阿,白里透着红,红里透着黑,黑不溜秋……绿了吧唧,蓝哇哇的,紫不溜秋…粉嘟嘟的透着那个美呀...
 
后退
顶部